Sofia Petrocchi

Dr. Sofia Petrocchi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ACAngela Capolupo
Angela Capolupo
SPSofia Petrocchi
Sofia Petrocchi
MMMaura Melchiorre
Maura Melchiorre
KJKim Jonas
Kim Jonas
TDThomas D'Hooghe
Thomas D'Hooghe
MLMonica Lispi
Monica Lispi
Highly purified human menopausal gonadotropin (HP-hMG [Menopur®, Ferring Pharmaceuticals, Saint-Prex, Switzerland]) contains a 1:1 ratio of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This analysis aimed to assess gonadotropin (FSH, LH and hCG) abundance in HP-hMG and clarify the source of hCG by assessing the presence of sulfated glycans, which are diagnostic for pituitary hCG forms due to their distinct glycosylation patterns. Additionally, the purity of each sample, their specific components, and their oxidation levels were assessed. HP-hMG samples (three of Menopur® and two of Menogon® Ferring Pharmaceuticals, Saint-Prex, Switzerland) were included in the current analyses. Brevactid® (urinary hCG; Ferring Pharmaceuticals, Saint-Prex, Switzerland) and Ovidrel® (recombinant hCG; Merck KGaA, Darmstadt, Germany) were used as control samples. Glycopeptide mapping and analysis of impurities were carried out by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Oxidation was assessed through reducing peptide mapping using LC-MS/MS. The FSH and LH in the HP-hMG samples showed sulfated glycans, while no signals of sulfated glycopeptides were detected on any site of the beta subunit of hCG. HP-hMG test samples presented the same hCG glycan distribution as the control sample (placental hCG, Brevactid®) extracted from the urine of pregnant women, suggesting a non-pituitary source of hCG. Protein impurities were estimated to constitute approximately 20–30% of the entire HP-hMG protein content in the test samples. More than 200 non-gonadotropin proteins were identified in the HP-hMG test samples, of which several were involved in embryonic development or pregnancy. The alpha subunit of the tested samples was strongly oxidized, with a relative abundance of 20% of the total gonadotropin content. Without taking into account all the protein impurities, the beta subunit of LH was detected only in traces (0.9–1.2%) in all tested HP-HMG samples, confirming the data obtained by intact molecule analysis, while high levels of beta hCG (18–47%) were observed. Advanced molecular analysis of HP-hMG indicates a primarily placental origin of hCG, as evidenced by the absence of hCG sulfated glycans and the predominance of placental non-sulfated hCG in LH activity. The analysis revealed 20–30% of protein impurities and a significant presence of oxidized forms in the HP-hMG samples. These findings are critical for understanding the quality, safety, and clinical profile of HP-hMG.

Verified
Journal Article
Open access
PDF file
ACAngela Capolupo
Angela Capolupo
FDFabio D'Amici
Fabio D'Amici
LBLuisa Buscajoni
Luisa Buscajoni
MFMattia Forchetta
Mattia Forchetta
SPSofia Petrocchi
Sofia Petrocchi
LGLuigi Guinta
Luigi Guinta
ENZ-124, the first approved cetuximab biosimilar by Indian health authorities, was developed using the Chinese hamster ovary cell line, whereas the SP2/0 cell line was used for developing cetuximab originator (Erbitux®). Hence, this assessment aimed to evaluate the physiochemical, structural, and biological characterization of four batches each of Cetuxa®, Lupitux® and cetuximab originator. Analytical methods like peptide mapping (liquid chromatography–tandem mass spectrometry [LC-MS/MS]), glycan mapping (liquid chromatography–fluorescence detection), isoform analysis (hydrophobic interaction chromatography [HIC]-high-performance liquid chromatography), charge variant analysis (capillary electrophoresis coupled with mass spectrometry), FcγRIIIa binding assays, cell-based antibody-dependent cell-mediated cytotoxicity (ADCC) measurement, and host cell protein analysis (LC-MS/MS) were utilized for analysis. Variations in physicochemical and biological attributes were observed between cetuximab originator and its biosimilars. HIC analysis revealed C-terminal heterogeneity and increased hydrophobicity in biosimilars, that with the different N-glycan profile affected charge distribution. Charge variant analysis indicated a more acidic profile for the biosimilars. The biosimilars showed higher oxidation levels and misincorporation. The biosimilars also showed an enhanced FcγRIIIa binding affinity and in vitro ADCC activation compared with cetuximab originator. The study outcomes highlight the ability to differentiate cetuximab originator from its biosimilars Cetuxa® and Lupitux® based on the observed physicochemical and biological differences.

22 August 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
FSFrancesca Sacco
Francesca Sacco
FBFabio Baroni
Fabio Baroni
ACAngela Capolupo
Angela Capolupo
SPSofia Petrocchi
Sofia Petrocchi
JZJonathan Zöller
Jonathan Zöller
MFMarco Fragai
Marco Fragai
Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This, in turn, brings about the importance of characterizing higher‐order protein structures at each stage, from production to patient. The flexibility and size of the mAbs often prevent achieving atomic‐level structural information in the pharmaceutical formulation by traditional methods. In this study, we introduce an integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1). With this approach, we were able to obtain epitope (by both NMR and HDX) and paratope mapping (by HDX), together with a detailed characterization of the structural rearrangements arising upon binding. This methodology provides both mechanistic and structural insights important for the design and optimization of biotherapeutics.

22 August 2026 in Angewandte Chemie
Verified
Journal Article
Open access
FSFrancesca Sacco
Francesca Sacco
FBFabio Baroni
Fabio Baroni
ACAngela Capolupo
Angela Capolupo
SPSofia Petrocchi
Sofia Petrocchi
JZJonathan Zöller
Jonathan Zöller
MFMarco Fragai
Marco Fragai
Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This, in turn, brings about the importance of characterizing higher‐order protein structures at each stage, from production to patient. The flexibility and size of the mAbs often prevent achieving atomic‐level structural information in the pharmaceutical formulation by traditional methods. In this study, we introduce an integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1). With this approach, we were able to obtain epitope (by both NMR and HDX) and paratope mapping (by HDX), together with a detailed characterization of the structural rearrangements arising upon binding. This methodology provides both mechanistic and structural insights important for the design and optimization of biotherapeutics.